How many shares can the new third board pharmaceutical companies share in the "green" consumption?

[market analysis of chinapharma.com] according to the "new third board +" app AILab, at present, 29 enterprises in the new third board are mainly engaged in traditional Chinese medicine extracts According to the semi annual report of 2017 disclosed by enterprises, 6 enterprises are market making transactions, 9 of which have a year-on-year drop in revenue and 5 enterprises have a negative net profit, mostly affected by the fluctuation of downstream market (how many shares can the new third board pharmaceutical companies share in the "green" consumption? Picture source: Baidu picture) China is rich in traditional Chinese medicine resources, is a big country of plant medicine, now has more than ten thousand kinds of medicinal plants With the spread of the concept of green consumption, plant extract products are more and more respected in the world, with a strong momentum of development "Green" consumption is coming, and China's industry exports account for more than 80% of the industry's total income Plant extract is a kind of product which takes plants as raw materials, according to the needs of the use of the extracted end products, through the physical and chemical extraction and separation process, directionally obtains and concentrates one or more of the total effective ingredients of plants, but does not change the structure of the effective ingredients, and has been widely used in medicine, health food and cosmetics In short, traditional Chinese medicine extract is a new kind of traditional Chinese medicine commodity which is prepared by modern medicine extraction method The concept of plant extract includes traditional Chinese medicine extract, which is a new traditional Chinese medicine product with new pharmaceutical technology In China, the main object of plant extract is Chinese herbal medicine, so the plant extract in China can also be called Chinese herbal medicine extract to some extent Traditional Chinese medicine extract has high requirements on production conditions and production technology Many advanced extraction, separation, purification, drying equipment and technology are applied to the production of traditional Chinese medicine extract, so it must be produced in accordance with the requirements of gap and GMP The main varieties of Chinese herbal extracts exported to foreign countries are: Ginkgo biloba, Hypericum perforatum, acanthopanax senticosus, angelica, ginseng and other extracts, mainly for export According to the "new third board +" app AILab, at present, 29 enterprises in the new third board are mainly engaged in the business of traditional Chinese medicine extract According to the 2017 half year report disclosed by the enterprise, 6 enterprises are market making transactions, 9 of which have the same ratio of revenue decline, 5 enterprises have negative net profit, mostly affected by the fluctuation of downstream market According to the statistics of 2017 half year report, Jiahe biology is a supplier of natural plant extracts and natural pharmaceutical intermediates Its products are mainly exported In 2017 half year, its revenue ranked the first in the new third board Chinese medicine extract industry with 430 million yuan, an increase of 26.24% year-on-year The reason for the increase is that the subsidiary Jiahe pharmaceutical industry put into production and operation, improved the production chain and improved production efficiency Caused by Jingjing pharmaceutical's half year revenue of 116 million yuan is mainly due to the company's overall operation maintaining a stable and positive trend; Knott's revenue increased by 36.74% year-on-year, the company said that it is the reason for the R & D investment and achievement transformation of new products From the perspective of net profit, Jiahe bio's net profit in 2017 was 50840100 yuan, ranking first in the industry; Jingjing pharmaceutical's net profit was 22.9828 million yuan, ranking second; Tianyi bio's net profit was 12.8291 million yuan, mainly due to the completion of new projects, transformation and capacity improvement Due to the low threshold and the scattered industry, the concentration of Chinese herbal extracts in China is not high However, in the market competition, with the elimination of enterprises with poor management and management, the industry concentration gradually increased, and a number of advantageous enterprises have emerged that can directly participate in international competition Jiahe biology has been in the forefront of the industry, and has been advancing with the main board enterprises Tiansheng pharmaceutical, Knott and Lingbei are also in the second tier According to Qianxun consulting and analysis, there are more than 1000 domestic professional extraction enterprises, large and small, with an annual export volume of more than 30 million yuan mainly distributed in Beijing and Tianjin, Shaanxi, Hunan, Sichuan, Yunnan and Guangxi, and the marketing mode has changed from passive to active Most of the Chinese medicine enterprises have their own extraction workshops, and most of the domestic plant extract products are mainly exported to Asia, Europe and the United States With the formation of industrialization trend and the continuous introduction of favorable industrial support policies, the plant extract industry will continue to maintain a high-speed development state, and it is expected that the industry scale will exceed 34.1 billion yuan in 2022 Original title: how many pieces of soup can the new third board enterprise with 30 billion Chinese medicine extraction scale share? Teach you to use app to seize the opportunity of pharmaceutical machine